[424B5] BioCardia, Inc. Prospectus Supplement (Debt Securities)
BCDA filed a prospectus supplement updating its at‑the‑market offering program for common stock through H.C. Wainwright & Co. The supplement sets a new maximum aggregate amount of $5,309,253 that may be sold under the program, after effectiveness and subject to offering conditions.
The company notes it has previously received approximately $3.9 million of gross proceeds from sales under the same program. Eligibility is based on an aggregate market value of non‑affiliate shares of approximately $20.1 million, calculated using 8,846,053 non‑affiliate shares at a $2.27 per‑share price as of September 11, 2025, and is constrained by Form S‑3 General Instruction I.B.6 (one‑third cap). During the 12‑month period ending on the date hereof, the company sold approximately $1.4 million pursuant to I.B.6.
BCDA ha depositato un supplemento al prospectus aggiornando il proprio programma di offerta sul mercato per azioni ordinarie tramite H.C. Wainwright & Co. Il supplemento stabilisce una nuova somma massima aggregata di $5,309,253 che può essere venduta nell'ambito del programma, dopo l'efficacia e soggetta alle condizioni di offerta.
L'azienda segnala di aver già ricevuto circa $3.9 milioni di proventi lordi dalle vendite nell'ambito dello stesso programma. L'idoneità si basa su un valore di mercato aggregato delle azioni non affiliate di circa $20.1 milioni, calcolato utilizzando 8.846.053 azioni non affiliate a un prezzo per azione di $2.27 al 11 settembre 2025, ed è soggetto al Modulo S-3 Istruzione Generale I.B.6 (limite di un terzo). Nel periodo di 12 mesi che termina alla data odierna, l'azienda ha venduto circa $1.4 milioni ai sensi di I.B.6.
BCDA presentó un suplemento de prospecto actualizando su programa de oferta en el mercado para acciones comunes a través de H.C. Wainwright & Co. El suplemento establece una nueva cantidad máxima agregada de $5,309,253 que puede ser vendida bajo el programa, después de la eficacia y sujeta a las condiciones de la oferta.
La empresa señala que ya ha recibido aproximadamente $3.9 millones de ingresos brutos por ventas bajo el mismo programa. La elegibilidad se basa en un valor de mercado agregado de acciones no afiliadas de aproximadamente $20.1 millones, calculado usando 8,846,053 acciones no afiliadas a un precio por acción de $2.27 al 11 de septiembre de 2025, y está restringida por la Forma S-3 Instrucción General I.B.6 (límite de un tercio). Durante el periodo de 12 meses que termina en la fecha de hoy, la empresa vendió aproximadamente $1.4 millones conforme a I.B.6.
BCDA는 H.C. Wainwright & Co.를 통한 보통주 시장가 마켓에서의 공모 프로그램을 업데이트하는 증권설명서 보충서를 제출했습니다. 보충서는 프로그램 하에서 매출될 수 있는 새로운 최대 총액 $5,309,253를 설정하며, 효력 발생 후 및 공모 조건에 따라 달라집니다.
회사는 동일한 프로그램 하에서 이미 약 $3.9백만의 총수익을 얻었다고 밝힙니다. 적격성은 비계열주식의 총시장가치가 약 $20.1백만으로 산정되며, 비계열주식 수 8,846,053주를 $2.27의 주당가로 계산하고 2025년 9월 11일 기준으로 이를 제시하며, S-3 양식 일반지침 I.B.6(일삼분의 일 제약)에 의해 제한됩니다. 이 날짜를 기준으로 12개월 동안 회사는 I.B.6에 따라 약 $1.4백만을 매도했습니다.
BCDA a déposé un supplément de prospectus actualisant son programme d'offre sur le marché pour les actions ordinaires via H.C. Wainwright & Co. Le supplément fixe un nouveau montant maximal global de $5,309,253 qui peut être vendu dans le cadre du programme, après efficacité et sous réserve des conditions d'offre.
La société indique avoir déjà reçu environ $3.9 millions de produits bruts de ventes dans le cadre du même programme. L'admissibilité est basée sur une valeur marchande globale des actions non affiliées d'environ $20.1 millions, calculée en utilisant 8,846,053 actions non affiliées à un prix par action de $2.27 au 11 septembre 2025, et est limitée par le Form S-3 Instruction générale I.B.6 (plafond d'un tiers). Au cours de la période de 12 mois se terminant à la date des présentes, la société a vendu environ $1.4 million conformément à I.B.6.
BCDA hat einen Prospektzusatz eingereicht, der sein at-the-market-Angebotsprogramm für Stammaktien über H.C. Wainwright & Co. aktualisiert. Der Zusatz legt einen neuen maximalen Gesamtbetrag von $5,309,253 fest, der gemäß dem Programm nach Wirksamkeit verkauft werden darf und unter Vorbehalt der Emissionsbedingungen steht.
Das Unternehmen weist darauf hin, dass es unter demselben Programm bereits ungefähr $3,9 Millionen Bruttoerlöse aus Verkäufen erhalten hat. Die Berechtigung basiert auf einem aggregierten Marktwert der nicht verbundenen Aktien von ca. $20.1 Millionen, berechnet unter Verwendung von 8.846.053 nicht verbundenen Aktien zu einem Stückpreis von $2.27 pro Aktie zum Stichtag 11. September 2025, und ist durch Form S-3 Allgemeine Anweisung I.B.6 (Drehtel-Grenze) eingeschränkt. Im zwölfmonatigen Zeitraum bis zu dem hier genannten Datum hat das Unternehmen ca. $1.4 Millionen gemäß I.B.6 verkauft.
BCDA قد قدمت ملحقاً للإفصاح يحدّث برنامج العرض في السوق للأسهم العادية عبر H.C. Wainwright & Co. يحدد الملحق مبلغاً إجمالياً أقصى جديداً يمكن بيعه بموجبه ضمن البرنامج قدره $5,309,253، وذلك بعد السريان وخاضع لشروط العرض.
تشير الشركة إلى أنها تلقت سابقاً نحو $3.9 مليون من العائد الإجمالي من المبيعات ضمن نفس البرنامج. الأهلية قائمة على قيمة سوقية مجمّعة لأسهم غير مرتبطة تبلغ نحو $20.1 مليون، محسوبة باستخدام 8,846,053 سهماً غير مرتبط بسعر $2.27 للسهم كما في 11 سبتمبر 2025، وهي مقيدة بالنموذج S-3 التعليمات العامة I.B.6 (حد أقصى لثُلث). خلال فترة 12 شهراً المنتهية في التاريخ المشار إليه هنا، باعت الشركة نحو $1.4 مليون وفقاً لـ I.B.6.
- None.
- None.
BCDA ha depositato un supplemento al prospectus aggiornando il proprio programma di offerta sul mercato per azioni ordinarie tramite H.C. Wainwright & Co. Il supplemento stabilisce una nuova somma massima aggregata di $5,309,253 che può essere venduta nell'ambito del programma, dopo l'efficacia e soggetta alle condizioni di offerta.
L'azienda segnala di aver già ricevuto circa $3.9 milioni di proventi lordi dalle vendite nell'ambito dello stesso programma. L'idoneità si basa su un valore di mercato aggregato delle azioni non affiliate di circa $20.1 milioni, calcolato utilizzando 8.846.053 azioni non affiliate a un prezzo per azione di $2.27 al 11 settembre 2025, ed è soggetto al Modulo S-3 Istruzione Generale I.B.6 (limite di un terzo). Nel periodo di 12 mesi che termina alla data odierna, l'azienda ha venduto circa $1.4 milioni ai sensi di I.B.6.
BCDA presentó un suplemento de prospecto actualizando su programa de oferta en el mercado para acciones comunes a través de H.C. Wainwright & Co. El suplemento establece una nueva cantidad máxima agregada de $5,309,253 que puede ser vendida bajo el programa, después de la eficacia y sujeta a las condiciones de la oferta.
La empresa señala que ya ha recibido aproximadamente $3.9 millones de ingresos brutos por ventas bajo el mismo programa. La elegibilidad se basa en un valor de mercado agregado de acciones no afiliadas de aproximadamente $20.1 millones, calculado usando 8,846,053 acciones no afiliadas a un precio por acción de $2.27 al 11 de septiembre de 2025, y está restringida por la Forma S-3 Instrucción General I.B.6 (límite de un tercio). Durante el periodo de 12 meses que termina en la fecha de hoy, la empresa vendió aproximadamente $1.4 millones conforme a I.B.6.
BCDA는 H.C. Wainwright & Co.를 통한 보통주 시장가 마켓에서의 공모 프로그램을 업데이트하는 증권설명서 보충서를 제출했습니다. 보충서는 프로그램 하에서 매출될 수 있는 새로운 최대 총액 $5,309,253를 설정하며, 효력 발생 후 및 공모 조건에 따라 달라집니다.
회사는 동일한 프로그램 하에서 이미 약 $3.9백만의 총수익을 얻었다고 밝힙니다. 적격성은 비계열주식의 총시장가치가 약 $20.1백만으로 산정되며, 비계열주식 수 8,846,053주를 $2.27의 주당가로 계산하고 2025년 9월 11일 기준으로 이를 제시하며, S-3 양식 일반지침 I.B.6(일삼분의 일 제약)에 의해 제한됩니다. 이 날짜를 기준으로 12개월 동안 회사는 I.B.6에 따라 약 $1.4백만을 매도했습니다.
BCDA a déposé un supplément de prospectus actualisant son programme d'offre sur le marché pour les actions ordinaires via H.C. Wainwright & Co. Le supplément fixe un nouveau montant maximal global de $5,309,253 qui peut être vendu dans le cadre du programme, après efficacité et sous réserve des conditions d'offre.
La société indique avoir déjà reçu environ $3.9 millions de produits bruts de ventes dans le cadre du même programme. L'admissibilité est basée sur une valeur marchande globale des actions non affiliées d'environ $20.1 millions, calculée en utilisant 8,846,053 actions non affiliées à un prix par action de $2.27 au 11 septembre 2025, et est limitée par le Form S-3 Instruction générale I.B.6 (plafond d'un tiers). Au cours de la période de 12 mois se terminant à la date des présentes, la société a vendu environ $1.4 million conformément à I.B.6.
BCDA hat einen Prospektzusatz eingereicht, der sein at-the-market-Angebotsprogramm für Stammaktien über H.C. Wainwright & Co. aktualisiert. Der Zusatz legt einen neuen maximalen Gesamtbetrag von $5,309,253 fest, der gemäß dem Programm nach Wirksamkeit verkauft werden darf und unter Vorbehalt der Emissionsbedingungen steht.
Das Unternehmen weist darauf hin, dass es unter demselben Programm bereits ungefähr $3,9 Millionen Bruttoerlöse aus Verkäufen erhalten hat. Die Berechtigung basiert auf einem aggregierten Marktwert der nicht verbundenen Aktien von ca. $20.1 Millionen, berechnet unter Verwendung von 8.846.053 nicht verbundenen Aktien zu einem Stückpreis von $2.27 pro Aktie zum Stichtag 11. September 2025, und ist durch Form S-3 Allgemeine Anweisung I.B.6 (Drehtel-Grenze) eingeschränkt. Im zwölfmonatigen Zeitraum bis zu dem hier genannten Datum hat das Unternehmen ca. $1.4 Millionen gemäß I.B.6 verkauft.
BCDA قد قدمت ملحقاً للإفصاح يحدّث برنامج العرض في السوق للأسهم العادية عبر H.C. Wainwright & Co. يحدد الملحق مبلغاً إجمالياً أقصى جديداً يمكن بيعه بموجبه ضمن البرنامج قدره $5,309,253، وذلك بعد السريان وخاضع لشروط العرض.
تشير الشركة إلى أنها تلقت سابقاً نحو $3.9 مليون من العائد الإجمالي من المبيعات ضمن نفس البرنامج. الأهلية قائمة على قيمة سوقية مجمّعة لأسهم غير مرتبطة تبلغ نحو $20.1 مليون، محسوبة باستخدام 8,846,053 سهماً غير مرتبط بسعر $2.27 للسهم كما في 11 سبتمبر 2025، وهي مقيدة بالنموذج S-3 التعليمات العامة I.B.6 (حد أقصى لثُلث). خلال فترة 12 شهراً المنتهية في التاريخ المشار إليه هنا، باعت الشركة نحو $1.4 مليون وفقاً لـ I.B.6.
BCDA 已提交一份招股说明书补充说明，更新其通过 H.C. Wainwright & Co. 进行的普通股在市场发行计划。该补充文件设定了一个新的可在该计划下出售的最大总额 $5,309,253，在生效后并受发行条件约束。
公司指出，已通过同一计划从销售中获得约 $3.9 million 的毛收益。资格基于非关联股的市场总值约 $20.1 million，以 8,846,053 只非关联股按每股 $2.27 的价格计算，截至 2025 年 9 月 11 日，并受表格 S-3 一般指令 I.B.6（三分之一封顶）的限制。在就此日期起的12个月期间，公司已根据 I.B.6 约定约出售约 $1.4 million。
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-275099
PROSPECTUS SUPPLEMENT
(To Prospectus dated December 5, 2023 and the Prospectus Supplements dated December 6, 2023, December 2, 2024, April 4, 2025, and July 8, 2025)
Up to $5,309,253
Common Stock
This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplemented by our prospectus supplement dated December 6, 2023, as further supplemented by the prospectus supplements dated December 2, 2024,April 4, 2025, and July 8, 2025 (as further supplemented, the “Initial Prospectus Supplement”, and, collectively with the base prospectus, the “Prospectus”), relating to the sale of shares of our common stock, $0.001 par value per share, from time to time through H.C. Wainwright & Co., LLC, as sales agent or principal, in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, pursuant to the Sales Agreement (as defined in the Prospectus).
This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus and any future amendments or supplements thereto.
Our common stock is listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “BCDA.” The last reported sale price of our common stock on the Nasdaq on October 23, 2025 was $1.395 per share.
We are filing this prospectus supplement to update the maximum aggregate offering amount of shares we are eligible to sell in this offering to $5,309,253, which amount is in addition to the approximately $3.9 million of gross proceeds we have received for sales of our common stock pursuant to the Sales Agreement under the Prospectus prior to the date of this prospectus supplement.
The aggregate market value of our outstanding common stock held by non-affiliates is approximately $20.1 million, based on 10,612,734 shares of outstanding common stock, of which 8,846,053 shares were held by non-affiliates, and a per share price of $2.27 based on the closing sale price of our common stock on September 11, 2025, which is the highest closing sale price of our common stock on the Nasdaq within the prior 60 days of this prospectus supplement. As a result, we are currently eligible to offer and sell up to an aggregate of approximately $5,309,253 of our securities under this prospectus supplement and the Prospectus. In no event will the aggregate offering amount of securities sold by us or on our behalf under this prospectus supplement pursuant to General Instruction I.B.6 of Form S-3 during the twelve-month period immediately prior to, and including, the date of any such sale, exceed one-third of the aggregate market value of our common stock held by non-affiliates in any 12 calendar month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75.0 million. During the 12 calendar month period that ends on and includes the date hereof, we have sold approximately $1.4 million of our shares of common stock pursuant to General Instruction I.B.6 of Form S-3.
Investing in our common stock involves significant risk. You should review carefully the risk factors described in, and incorporated by reference under, “Risk Factors” beginning on page S-3 of the Initial Prospectus Supplement and page 3 of the accompanying base prospectus before investing in our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
The date of this prospectus supplement is October 24, 2025
